Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Hepatitis B virus test, Maternal exposure during pregnancy, Rubivirus test positive, Ultrasound abdomen
Clinical narrative: Headache; Fatigue; Gestation period at time of initial exposure 2 months, 1 trimester. Maternal exposure during pregnancy; This is a spontaneous report from a contactable nurse (the patient). A 38-year-old pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3248, expiration date: Apr2021), via intramuscular route of administration, in the left arm, on 23Jan2021 (at the age of 38-year-old), as single dose for COVID-19 immunization at hospital. The patient's medical history included ongoing diabetes from 2013, controlled with diet and exercise; ongoing depression from 2000 and taking medication; ongoing pregnancy from Nov2020 with high-risk, pseudotumor cerebri, PCOS (Polycystic ovarian syndrome), weight loss sx, 2 times miscarriage and previously taking Tylenol (500 mg oral) from 02Jan2021, prior to vaccine. Concomitant medications included escitalopram oxalate (LEXAPRO, 20 mg daily) for depression, ascorbic acid, betacarotene, calcium sulfate, colecalciferol, cyanocobalamin, ferrous fumarate, folic acid, nicotinamide, pyridoxine hydrochloride, retinol acetate, riboflavin, thiamine mononitrate, tocopheryl acetate, zinc oxide (PRENATAL VITAMINS, 1 tab daily) for pregnancy from 15Nov2020, calcium, colecalciferol (VITAMIN D3 CALCIUM, 1 chew 3 times daily) for weight loss sx from 2019, acetylsalicylic acid (ASPIRINE, 81 mg daily, Bayer chewable) for pregnancy from 15Nov2020, ubidecarenone (COQ10, 200 mg daily) for pregnancy from 2020 and fish oil for pregnancy from 2020, 1 tab 2 times daily. The patient's historical vaccine included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EH9899, expiration date: Mar2021), via intramuscular route of administration, in the left arm, on 02Jan2021 at 15:10 (at the age of 38-year-old), as single dose, for COVID-19 immunization at hospital and patient experienced the headache on 02Jan2021 at 16:00 on dose 1. Patient's first day of last menstrual period was 25Oct2020, estimated date of conception was 15Nov2020 and estimated delivery date would be 01Aug2021. Patient did not smoke, drink alcohol and use illicit drugs during this pregnancy. No prior vaccinations within 4 weeks. Patient did not require any visit to emergency room and physician office. On 23Jan2021 at 23:00, patient experienced headache, fatigue. Gestation period at time of initial exposure 2 months, 1 trimester. Maternal exposure during pregnancy. Patient was not admitted to hospital. There were not any adverse events considered serious due to being life threatening, or due to persistent or significant disability/Incapacity or any other reason. The patient underwent the lab tests and procedure which included the ante-natal check-up: serum maker: not reported on 22Nov2020, ultrasound AB: less than 14 weeks on 11Dec2020 and results of serology tests included rubella test - positive; chlamydia test - negative; hep-B test - negative; HIV test - negative. No treatment was required. Reporter reported that events had causal relationship with vaccine. Outcome of the events headache, fatigue was recovered on an unknown date in 2021.   Information on lot/batch number was available. Additional information has been requested.